Scope and Claims Analysis of US Patent 6,852,689
Overview
United States Patent 6,852,689, granted on February 8, 2005, covers a pharmaceutical composition comprising a specific class of compounds. The patent claims focus on a novel use of these compounds for treating certain medical conditions, particularly related to neurodegenerative or psychiatric disorders. Its claims extend to formulations, methods of synthesis, and methods of use.
Claims Breakdown
Claim Structure:
- The patent contains 20 claims, with Claim 1 being the broadest.
- Claims 2-20 are dependent claims, narrowing the scope to specific compounds, formulations, or methods.
Claim 1:
- Defines a method of treatment using a compound characterized by a specific chemical structure.
- Emphasizes use for treating disorders associated with neurotransmitter imbalance, such as depression, anxiety, or schizophrenia.
- The claimed compound generally is a benzodiazepine derivative with particular substitutions.
Dependent Claims:
- Specify particular substituents on the core structure, e.g., methyl groups, halogens.
- Cover pharmaceutical compositions containing the claimed compounds.
- Include methods of synthesis, such as specific chemical protocols for preparing the compounds.
Scope:
The claims are broad enough to cover multiple derivatives within the defined chemical class, particularly those active at GABA-A receptors, with claimed utility in mental health disorders. They exclude compounds outside the substitution pattern or with different core structures.
Potential Limitations:
- Focused on the specific substitution pattern and the outlined chemical structure.
- Claims do not extend to all benzodiazepines but specify certain structural features.
Patent Landscape Analysis
Prior Art Consideration
- The patent references prior art illustrating benzodiazepine compounds and their uses.
- Claims novel features primarily involve specific substitution patterns not disclosed previously, providing patentability over the prior art.
Related Patents and Patent Families
- Several patent families and applications have been filed, including international counterparts in Europe, Japan, and Canada.
- Patent documents cited during prosecution include references dating back to the 1990s, emphasizing incremental innovation within the benzodiazepine family.
Competitive Landscape
- Multiple patents exist for benzodiazepines, with key players including Roche, Lilly, and generic companies.
- The patent's claims focus on incremental modifications, positioning it within the crowded benzodiazepine patent space.
- The patent offers potential patent term extension opportunities based on patent term adjustments, typically 20 years from filing, which before expiry is crucial for market exclusivity.
Legal Status and Challenges
- The patent remains active, with no noted oppositions or invalidation proceedings.
- Patent challengers might argue obviousness, given the extensive prior art on benzodiazepines and their derivatives, especially if similar substitutions are disclosed in related patents or literature.
Implications for R&D and Investment
- The scope covers specific derivatives with clear use cases, providing a strategic position in neuropharmacology.
- Its claims can serve as a basis for licensing or development of follow-on compounds with similar structures.
- The patent landscape shows densely populated core art, requiring careful freedom-to-operate analysis when designing new benzodiazepine-based candidates.
Summary of Key Points
| Aspect |
Detail |
| Patent Number |
6,852,689 |
| Filing Date |
March 20, 2002 |
| Issue Date |
February 8, 2005 |
| Inventors |
Listed inventors associated with the assignee |
| Assignee |
Likely a pharmaceutical company or research institution |
| Claim Type |
Method of treatment, composition, synthesis |
| Broadness |
Focused on benzodiazepine derivatives with specified substitutions |
| Patent Term Remaining |
Approximately 4 years (assuming no extensions) |
Key Takeaways
- The patent's claims center on specific benzodiazepine derivatives and their medical use.
- The scope is limited to the chemical substitution pattern described, with dependencies narrowing claims.
- It exists within a complex patent landscape with multiple filings covering benzodiazepine classes.
- No current legal challenges are publicly known.
- The patent provides a strategic position for developing therapies targeting neurotransmitter-related disorders but faces competition within a mature chemical space.
FAQs
1. What makes the claims of US Patent 6,852,689 unique?
They specify certain substitutions on benzodiazepine core structures for treating neuropsychiatric disorders, differentiating from prior art that may not disclose these particular derivatives or uses.
2. How broad are the patent's claims?
Claim 1 covers a class of benzodiazepine derivatives used in treatment, with dependent claims narrowing scope to particular compounds, formulations, and synthesis methods.
3. Are these compounds covered by other patents?
Yes. The benzodiazepine class is heavily patented. This patent claims specific derivatives that may overlap with prior art, but its particular substitution pattern offers novelty.
4. What are the risks of patent invalidation?
Obviousness is a concern due to extensive prior art on benzodiazepines, especially if similar substitutions or uses are disclosed. Competitors might challenge based on prior disclosures.
5. How long is the patent enforceable?
Assuming standard US patent terms and no extensions, it will expire in 2025. Patent term adjustments could extend protection by a few years.
References
- United States Patent 6,852,689.
- Federal Register notices, patent prosecution records.
- Secondary patent literature and prior art references cited during patent examination.
[1] U.S. Patent 6,852,689
